Edwards Lifesciences Corp. (EW)
NYSE:EW
Want to see EW full AI Analyst Report?
EW Stock Chart & Stats
$80.99
$0.80(1.09%)
At close: 4:00 PM EST
$80.99
$0.80(1.09%)
Day’s Range― - ―
52-Week Range$72.30 - $88.28
Previous CloseN/A
Volume821.68K
Average Volume (3M)5.33M
Market Cap
$50.47B
Enterprise Value$48.05B
Total Cash (Recent Filing)$3.67B
Total Debt (Recent Filing)$702.90M
Price to Earnings (P/E)46.5
Beta0.58
Next Earnings
Jul 23, 2026EPS Estimate
0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.89
Shares Outstanding575,800,000
10 Day Avg. Volume5,179,364
30 Day Avg. Volume5,333,534
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)4.82
Price to Sales (P/S)8.22
P/FCF Ratio37.34
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue7.62
Enterprise Value/Gross Profit9.77
Enterprise Value/Ebitda33.47
Forecast
1Y Price Target
$98.27Price Target Upside21.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)3.01
Revenue Forecast (FY)$6.76B
Bulls Say, Bears Say
Bulls Say
High Gross And Operating MarginsSustained high gross and operating margins indicate durable pricing power and efficient manufacturing in implantable devices. These margins support continued R&D, clinical evidence generation and physician training investments that underpin long-term adoption of its structural heart portfolio and resilience to cost pressure.
Conservative Balance Sheet, Low LeverageVery low leverage gives the company financial flexibility to fund R&D, clinical trials, and selective M&A without stressing cash flow. It also provides resilience to reimbursement or hospital budget volatility and supports multi-year investments in commercial expansion and product development.
Market Leadership In Structural Heart And Recurring ConsumablesLeading position in TAVR and structural heart therapies plus recurring critical-care consumables creates a mix of durable high-value implants and repeatable consumable sales. This combination drives sustainable revenue streams, clinician stickiness and long-term program-level hospital relationships.
Bears Say
Subdued Revenue GrowthModest top-line growth limits the company's ability to rely on scale to offset margin pressure or fund accelerated R&D organically. Slower procedure growth and periodic declines increase dependence on new indications, geographic expansion and higher-cost commercialization to reignite sustainable revenue momentum.
Weaker Cash Conversion RecentlyDeclining free cash flow conversion reduces financial flexibility for share repurchases, large investments, or bolt‑on acquisitions. If operating cash remains below net income, the company may face harder tradeoffs between funding clinical programs and returning capital, affecting multi-year strategy execution.
Expanded Equity Incentive PoolA materially larger equity award capacity helps recruit and retain senior talent but raises dilution risk over time. Expanded share-based compensation can increase share count and pressure per-share metrics, complicating capital allocation decisions and potentially reducing shareholder returns if not offset by stronger growth.
Edwards Lifesciences News
EW FAQ
What was Edwards Lifesciences Corp.’s price range in the past 12 months?
Edwards Lifesciences Corp. lowest stock price was $72.30 and its highest was $88.28 in the past 12 months.
What is Edwards Lifesciences Corp.’s market cap?
Edwards Lifesciences Corp.’s market cap is $50.47B.
When is Edwards Lifesciences Corp.’s upcoming earnings report date?
Edwards Lifesciences Corp.’s upcoming earnings report date is Jul 23, 2026 which is in 50 days.
How were Edwards Lifesciences Corp.’s earnings last quarter?
Edwards Lifesciences Corp. released its earnings results on Apr 23, 2026. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.729 by $0.051.
Is Edwards Lifesciences Corp. overvalued?
According to Wall Street analysts Edwards Lifesciences Corp.’s price is currently Undervalued.
Does Edwards Lifesciences Corp. pay dividends?
Edwards Lifesciences Corp. does not currently pay dividends.
What is Edwards Lifesciences Corp.’s EPS estimate?
Edwards Lifesciences Corp.’s EPS estimate is 0.74.
How many shares outstanding does Edwards Lifesciences Corp. have?
Edwards Lifesciences Corp. has 575,800,000 shares outstanding.
What happened to Edwards Lifesciences Corp.’s price movement after its last earnings report?
Edwards Lifesciences Corp. reported an EPS of $0.78 in its last earnings report, beating expectations of $0.729. Following the earnings report the stock price went up 5.557%.
Which hedge fund is a major shareholder of Edwards Lifesciences Corp.?
Currently, no hedge funds are holding shares in EW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edwards Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$98.27 (21.33% Upside)
$98.27 (21.33% Upside)
Blogger Sentiment
Bullish
EW Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.5%
Last 30 Days ▲ 9.5%
Last 30 Days ▲ 9.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.70%
12-Months-Change
Fundamentals
Return on Equity
10.55%
Trailing 12-Months
Asset Growth
2.30%
Trailing 12-Months
Company Description
Edwards Lifesciences Corp.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
EW Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a broadly positive outlook: the company delivered strong top‑line growth (Q4 +11.6%, FY +10.7%), robust TAVR and TMTT momentum, and reiterated confident 2026 guidance (8%–10% sales growth; EPS $2.90–$3.05). Key positives include compelling long‑term clinical evidence, successful product launches (SAPIEN M3, NextGen PASCAL), margin discipline and a healthy balance sheet. Near‑term headwinds are primarily deliberate investments in patient access and field resources (driving higher SG&A), one‑time GAAP charges (GennaValve/litigation), an elevated tax rate in the quarter, and distributor inventory adjustments that modestly impacted surgical sales. Management frames the incremental spending as strategic and expects margin expansion over time. Overall, the positive operational and strategic catalysts outweigh the one‑time and timing‑related negatives.View all EW earnings summariesEW Net sales Breakdown
73.96% Transcatheter Aortic Valve Replacement
9.07% Transcatheter Mitral and Tricuspid Therapies
16.96% Surgical Structural Heart
EW Stock 12 Month Forecast
Average Price Target
$98.27
▲(21.33% Upside)
Technical Analysis
Ownership Overview
0.22% Insiders
25.18% Mutual Funds
17.94% Other Institutional Investors
32.03% Public Companies and
Individual Investors